Drug intelligence / Profile preview

HP-508

Development stage: Unknown
Lead developer: Housey Pharmaceutical Research Laboratories
Modality: Small Molecules

Overview

HP-508 is an experimental small molecule therapeutic candidate being developed by Housey Pharmaceutical Research Laboratories for the treatment of Type 1 Diabetes. Discovered using the company's proprietary cell-based assay systems, HP-508 is designed to stimulate the regeneration of pancreatic beta cells. This approach aims to restore endogenous insulin production in patients whose beta cells have been destroyed by autoimmune processes, potentially reducing or eliminating the need for exogenous insulin therapy. The candidate is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on HP-508.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-508.

Explore the full profile